Drug insight: Bisphosphonates for postmenopausal osteoporosis

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 4, 2006, Pages 211-219

  Chapurlat, Roland D ^a   Delmas, Pierre D ^a,b,c  

^a UNIVERSITÉ LYON 1   (France)

^b INSERM   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Alendronate; Bisphosphonates; Ibandronate; Osteoporosis; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GERANYLTRANSFERASE; IBANDRONIC ACID; MEVALONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

APOPTOSIS; BONE MATRIX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ENZYME INHIBITION; ESOPHAGITIS; FEVER; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; MYALGIA; OSTEOCLAST; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; THROMBOPHLEBITIS; UVEITIS; VERTEBRA FRACTURE;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 33646565019     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0121     Document Type: Review

References (50)

1. Fleisch HA (ed.; 1997) Bisphosphonates in Bone Disease. In From the Laboratory to the Patient, edn 3. New York: Parthenon Publishing
2. Russell RGG et al. (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 10 (Suppl 2): S66-S80
3. Papapoulos SE (2001) Bisphosphonates in the management of postmenopausal osteoporosis. In Osteoporosis, edn 2, 631-650 (Eds Marcus R et al.) San Diego: Academic Press
4. Lin JH et al. (1992) Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos 20: 608-613
5. Lin JH et al. (1993) The role of calcium in plasma protein binding and renal handling of alendronate in hyper- and hypocalcemic rats. J Pharmacol Exp Ther 267: 670-675
6. Riis BJ et al. (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16: 1871-1878
7. Tanko LB et al. (2003) Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 32: 687-693
8. Pedersen-Bjergaard U and Myhre J (1991) Severe hypocalcaemia after treatment with diphosphonate and aminoglycoside. BMJ 302: 295
9. Salo J et al. (1997) Removal of osteoclast bone resorption products by transcytosis. Science 276: 270-273
10. Rogers MJ et al. (1994) Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. J Bone Miner Res 9: 1029-1039
11. Frith JC et al. (1996) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-β,γ- dichlormethylene triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358-1367
12. Luckman SP et al. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589
13. Ridley AJ and Hall A (1992) The small GTP-binding-protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389-399
14. Dunford JE et al. (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242
15. Vitte C et al. (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137: 2324-2333
16. Plotkin LI et al. (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104: 1363-1374
17. Giuliani N et al. (1998) Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22: 455-461
18. Chavassieux PM et al. (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 1475-1480
19. Boivin GY et al. (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27: 687-694
20. Nancollas GH et al. (2005) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone [doi:10.1016/j.bone.2005.05.003]
21. McClung M et al. (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Int Med 128: 253-261
22. Liberman UA et al. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443
23. Black DM et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535-1541
24. Cummings SR et al. (1998) Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures. JAMA 280: 2077-2082
25. Ensrud KE et al. (1997) Treatment with alendronate prevents fractures in women at highest risk. Arch Int Med 157: 2617-2624
26. Nevitt MC et al. (2000) Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Int Med 160: 77-85
27. Rizzoli R et al. (2002) Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17: 1988-1996
28. Bone HG et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199
29. Black DM et al. (2004) A 5 year randomized trial of the long-term efficacy and safety of alendronate: the FIT Long-term Extension (FLEX). J Bone Miner Res 19 (Suppl 1): S45
30. Bauer DC et al. (2005) Increased bone turnover after discontinuing alendronate predicts bone loss over 5 years: the FLEX Study. J Bone Miner Res 20 (Suppl 1): S95
31. Recker RR et al. (2004) Normal bone histomorphometry and 3D microarchitecture after 10 years of alendronate treatment of postmenopausal women. J Bone Miner Res 19 (Suppl 1): S45
32. Harris ST et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282: 1344-1352
33. Reginster J-Y et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11: 83-91
34. McClung MR et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333-340
35. Mitchell DY et al. (2000) Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 40: 258-265
36. Brown JP et al. (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal women. Calcif Tissue Int 71: 103-111
37. Mellström DD et al. (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75: 462-468
38. Watts NB et al. (2004) Effect of risedronate treatment discontinuation on bone turnover and BMD. Calcif Tissue Int 74 (Suppl 1): S79
39. Ste-Marie LG et al. (2004) Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75: 469-476
40. Tanko LB et al. (2003) Oral weekly ibandronate prevents bone loss in postmenopausal women. J Int Med 254: 159-167
41. Chestnut CH III et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241-1249
42. Miller PD et al. (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 20: 1315-1322
43. Recker RR et al. (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34: 890-899
44. Adami S et al. (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34: 881-889
45. Reid IR et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346: 653-661
46. Rosen CF et al. (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20: 141-151
47. Mashiba T et al. (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15: 613-620
48. Mashiba T et al. (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in Beagles. Bone 28: 524-531
49. Komatsubara S et al. (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18: 512-520
50. Allen MR et al. (2005) Risedronate and alendronate similarly suppress bone remodeling and increase microdamage in Beagles after 1 year of treatment at clinical doses. J Bone Miner Res 20 (Suppl 1): S22